Home › Non-Small Cell Lung Cancer › NCT07100080

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

RecruitingPhase 2/3

IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy

Who can join

Ages 18 and older · All sexes

Full eligibility criteria

Inclusion Criteria:

* Non-squamous NSCLC, not amenable to treatment in curative intent.
* Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation).
* Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting.
* Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin) in combination with pemetrexed with or without amivantamab.

Exclusion criteria:

* Inadequate organ function and/or bone marrow reserve.
* Leptomeningeal metastases or spinal cord compression.
* Poorly controlled systemic medical conditions.
* Other protocol-defined inclusion/exclusion criteria apply.

About the study

A study of Izalontamab Brengitecan (BMS-986507) versus platinum-based chemotherapy with or without Amivantamab for EGFR-mutated non-small cell lung cancer after failure of EGFR TKI therapy

What is being tested

Iza-bren (drug)
Carboplatin (drug)
Cisplatin (drug)
Pemetrexed (drug)
Amivantamab (drug)

Sponsor: Bristol-Myers Squibb · Participants: 661 · Started: Nov 5, 2025

Contact the study team

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · Phone: 855-907-3286

Official record on ClinicalTrials.gov — NCT07100080

Locations in the U.S.

California	UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building, Irvine University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Colorado	Shaw Cancer Center, Edwards
Florida	Local Institution - 0142, Pembroke Pines (Not yet recruiting)
Georgia	Piedmont Healthcare, Atlanta John B Amos Cancer Center, Columbus
Illinois	Rush University Medical Center, Chicago
Massachusetts	Dana-Farber Cancer Institute, Boston
Missouri	Washington University School of Medicine, St Louis
Nevada	Renown Regional Medical Center, Reno
New York	Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola NYU Langone Health, New York Weill Cornell Medical College, New York Rochester General Hospital Infectious Disease, Rochester
Ohio	University Hospitals Cleveland Medical Center, Cleveland The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus
Oregon	Oregon Health and Science University, Portland Providence Cancer Institute Franz Clinic, Portland Providence St. Vincent Medical Center, Portland
Pennsylvania	Hospital of the University of Pennsylvania, Philadelphia West Penn Allegheny Health, Pittsburgh
Tennessee	Tennessee Oncology, Nashville
Texas	University of Texas MD Anderson Cancer Center, Houston Local Institution - 0173, San Antonio (Not yet recruiting)
Virginia	University of Virginia Health System, Charlottesville Virginia Commonwealth University (Vcu), Richmond

Conditions

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.